Literature DB >> 10223617

Enzyme therapy in Gaucher disease type 2: an autopsy case.

T Takahashi1, Y Yoshida, W Sato, T Yano, Y Shoji, Y Sawaishi, I Sakuma, T Sashi, K Enomoto, H Ida, G Takada.   

Abstract

A Japanese patient with Gaucher disease type 2 was treated with enzyme therapy, alglucerase, from 7 to 22 months of age. Whereas hematologic parameters were normalized and hepatosplenomegaly was alleviated, no improvement in neurologic symptoms occurred, and the patient died of respiratory failure at age 22 months. Postmortem examination revealed massive intra-alveolar infiltration of Gaucher cells in lungs and in the central nervous system, i.e., the presence of Gaucher cells in the perivascular Virchow-Robins spaces in the cortex and deep white matter and extensive lamilar necrosis with reactive proliferation of blood vessels and macrophage infiltration of the cerebral cortex. It is suggested that enzyme therapy, with thus far recommended dose, does not prevent long-term respiratory and central nervous system involvement in severe varients of Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10223617     DOI: 10.1620/tjem.186.143

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  2 in total

1.  A model of neuronopathic Gaucher disease.

Authors:  P E Campbell; C M Harris; C M Harris; T Sirimanna; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

2.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.